Virtual Library
Start Your Search
C. Çam
Author of
-
+
P3.07 - Immunology and Immunotherapy (ID 723)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.07-010 - T Helper 17 Cell Related Cytokines as a Prognostic Factor in Lung Cancer Patients (ID 9188)
09:30 - 09:30 | Author(s): C. Çam
- Abstract
Background:
T Helper 17 (Th17) cells play roles in several biological processes including malignancy. Most important Th17 related cytokines are interleukin-17 (IL-17) and IL-23. We reported previously that serum IL-23 levels are elevated in lung cancer patients and IL-17 and IL-23 values are correlated inflammatory markers (1). In this study, the prognostic effects of these cytokines have been evaluated with long follow-up data.
Method:
: Forty-six lung cancer patients are included to the study. Data of patients were achieved from clinic archive, hospital computed system, and previously study records (1). The median values of levels IL-17 and IL-23 were calculated, and the patients have been categorized as high (higher of median value) and low levels separately of IL-17 and IL-23. Survival analyses were analyzed with log rank test, survival curves were constructed with Kaplan Meier test.
Result:
The patients have been followed for a median time of 30.7 months (range: 2.0 to 194.4 months). Locally advanced, metastatic non-small cell lung cancer (NSCLC), limited stage, and extended stage small cell lung cancer (SCLC) patients have been analyzed separately. Because number of limited disease SCLC patients was little, they have not been evaluated. When high IL-17 group compare with low IL-17 group, overall survival times were not different in locally advanced NSCLC patients. Among metastatic NSCLC patients, low IL-17 group has numerically -but not significant- longer median overall survival time (MS: 36 (17.2 to 78.9) months vs 15.65 (3.2 to 76.9) months; p=0.4). The patients with extended stage SCLC and low IL-17 have been survived longer time compared those with high IL-17 (MS: 36.3 (14.0 to 41.3) months vs 9.8 (4.1 to 13.8) months; p=0.003). When high IL-23 group compare with low IL-23 group, overall survival times were not different in locally advanced, metastatic NSCLC and extended stage SCLC patients.
Conclusion:
Serum IL-17 levels may be prognostic factor in advanced stage lung cancer patients, particularly those with SCLC. In this situation, further studies are needed.
